

SUPPLEMENTARY MATERIALS

Cytotoxicity evaluation of unmodified paddlewheel dirhodium(II,II)-acetate/-formamidinate complexes and their axially modified low-valent metallocendrimers

Stephen de Doncker ¹, Eva Fischer-Fodor ², Cătălin Ioan Vlad ^{3,4},
Patriciu Achimas-Cadariu ^{3,4}, Gregory S. Smith ^{1,*} and Siyabonga Ngubane ^{1,*}

¹ Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7701, South Africa

² Tumour Biology Department, The Oncology Institute “Prof. Dr. Ion Chiricuta”, 400015 Cluj-Napoca, Romania

³ Department of Surgery, The Oncology Institute, “Prof. Dr. Ion Chiricuță”, 400015 Cluj-Napoca, Romania

⁴ Department of Surgery and Gynecological Oncology, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania

Table of Contents

Content

Cover Page.....	1
Table of contents.....	2
Figure S1. Infrared spectrum obtained for 8	3
Figure S2. Infrared spectrum obtained for 9	3
Figure S3. Infrared spectrum obtained for 10	4
Figure S4. HR-ESI-MS spectrum obtained for 8	4
Figure S5. HR-ESI-MS spectrum obtained for 9	5
Figure S6. HR-ESI-MS spectrum obtained for 10	5
Figure S7. TGA trace obtained for 9	6
Figure S8. Electronic absorption spectra of 8 in DMSO collected at t = 0, 2 and 48 h.....	6
Figure S9. Electronic absorption spectra of 9 in DMSO collected at t = 0, 2 and 48 h.....	7
Figure S10. Electronic absorption spectra of 10 in DMSO collected at t = 0, 2 and 48 h	7
Figure S11. Dose-response curves for 1-6, 8-10 and cisplatin in the A2780 cell line.....	8
Figure S12. Dose-response curves for 1-6, 8-10 and cisplatin in the A2780 _{cis} cell line.....	8
Figure S13. Dose-response curves for 1-6, 8-10 and cisplatin in the OVCAR-3 cell line.....	9
Figure S14. Dose-response linear regression of optical density <i>versus</i> concentration, in ovarian tumor cells subjected to treatment for 24 hours.....	10
Table S1. The cell growth inhibitory capacity of formamidinate ligands (1, 2), dirhodium(II,II) complexes (3 - 10) and cisplatin in cancer cell lines.....	11




Figure S1. Infrared spectrum obtained for **8**




Figure S2. Infrared spectrum obtained for **9**.






Figure S3. Infrared spectrum obtained for **10**.



(**8**)

Figure S4. HR-ESI-MS spectrum obtained for **8**.





Figure S5. HR-ESI-MS spectrum obtained for **9**.





Figure S6. HR-ESI-MS spectrum obtained for **10**.




Figure S7. TGA trace obtained for compound **9**.




Figure S8. UV-vis stability of complex **8** in DMSO collected at $t = 0, 2$ and 48 h .




Figure S9. Electronic absorption spectra of **9** in DMSO collected at $t = 0, 2$ and 48 h .




Figure S10. Electronic absorption spectra of **10** in DMSO collected at $t = 0, 2$ and 48 h .

A2780




Figure S11. Dose-response curves for **1-6, 8-10** and cisplatin in the A2780 cell line.

A2780*cis*




Figure S12. Dose-response curves for **1-6, 8-10** and cisplatin in the A2780*cis* cell line.




Figure S13. Dose-response curves for **1-6**, **8-10** and cisplatin in the OVCAR-3 cell line.




Figure S14. Dose-response linear regression of optical density *versus* concentration, in ovarian tumor cells subjected to treatment for 24 hours.

Table S1. The cell growth inhibitory capacity of formamidinate ligands (**1**, **2**), dirhodium(II,II) complexes (**3 - 10**) and cisplatin in cancer cell lines (A2780, A2780*cis*, OVCAR-3), analyzed by linear regression hillslope (steepness of the line) significance in the 95% confidence interval. All hillslope values are negative, confirming that a relationship was established between the compounds concentration and the cell growth inhibition; the tendency to inhibit is more evident when r^2 fraction is closer to 1, and p value<0.05 indicates statistical significance. Where p>0.05, the growth inhibition is independent of the doses, up to 100 μ M.

		A2780			A2780 <i>cis</i>			OVCAR-3		
Compound	n	Hillslope	r^2	p value	Hillslope	r^2	p value	Hillslope	r^2	p value
1	0	-0.0010 ± 0.0002	0.50	0.0002	-0.00073 ± 0.00075	0.074	0.4166*	- 0.000032 ± 0.00017	0.0025	0.8664*
2	0	-0.0056 ± 0.00027	0.97	0.0138	-0.0012 ± 0.00044	0.39	0.0163	-0.00025 ± 0.00020	0.099	0.2353*
3	2	-0.0036 ± 0.00065	0.65	<0.0001	-0.0041 ± 0.00095	0.61	0.0025	-0.00092 ± 0.00017	0.68	0.0009
4	2	-0.0035 ± 0.00081	0.54	0.0021	-0.0040 ± 0.00078	0.66	0.0013	-0.00054 ± 0.00023	0.28	0.0355
5	2	-0.0055 ± 0.00038	0.93	<0.0001	-0.0054 ± 0.00042	0.93	<0.0001	-0.00075 ± 0.00013	0.69	<0.0001
6	2	-0.0031 ± 0.00070	0.56	<0.0001	-0.0019 ± 0.00049	0.56	0.0231	-0.00023 ± 0.00013	0.18	0.1012*
8	6	-0.0027 ± 0.00047	0.71	<0.0001	-0.0027 ± 0.00030	0.87	<0.0001	-0.0012 ± 0.00024	0.65	0.0003
9	6	-0.0017 ± 0.00033	0.65	0.0037	-0.00093 ± 0.00071	0.12	0.1436*	-0.00021 ± 0.00020	0.082	0.0628*
10	6	-0.0016 ± 0.00036	0.57	0.0010	-0.0011 ± 0.00047	0.30	0.0408	-0.00023 ± 0.00019	0.059	0.6159*
Cisplatin	1	-0.0044 ± 0.00099	0.58	<0.0001	-0.0039 ± 0.00044	0.85	<0.0001	-0.0015 ± 0.00023	0.76	<0.0001

n- number of metal atoms per molecule; r^2 - correlation coefficient, goodness of fit; * p>0.05, no significant cell growth inhibition.